Clinical Trial Update: A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of GSK2110183 for Langerhans Cell Histiocytosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• GSK2110183

Snippet

Sponsor: GlaxoSmithKline | Conditions: Langerhans Cell Histiocytosis | Phase 2 | Status: COMPLETED